397 related articles for article (PubMed ID: 24492980)
1. Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages.
Rombach SM; Smid BE; Linthorst GE; Dijkgraaf MG; Hollak CE
J Inherit Metab Dis; 2014 May; 37(3):341-52. PubMed ID: 24492980
[TBL] [Abstract][Full Text] [Related]
2. Fabry Disease and the Effectiveness of Enzyme Replacement Therapy (ERT) in Left Ventricular Hypertrophy (LVH) Improvement: A Review and Meta-Analysis.
Lee CL; Lin SP; Niu DM; Lin HY
Int J Med Sci; 2022; 19(1):126-131. PubMed ID: 34975306
[No Abstract] [Full Text] [Related]
3. Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease.
Fellgiebel A; Gartenschläger M; Wildberger K; Scheurich A; Desnick RJ; Sims K
Cerebrovasc Dis; 2014; 38(6):448-56. PubMed ID: 25502511
[TBL] [Abstract][Full Text] [Related]
4. Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain.
Rombach SM; Smid BE; Bouwman MG; Linthorst GE; Dijkgraaf MG; Hollak CE
Orphanet J Rare Dis; 2013 Mar; 8():47. PubMed ID: 23531228
[TBL] [Abstract][Full Text] [Related]
5. Renal function predicts long-term outcome on enzyme replacement therapy in patients with Fabry disease.
Lenders M; Schmitz B; Stypmann J; Duning T; Brand SM; Kurschat C; Brand E
Nephrol Dial Transplant; 2017 Dec; 32(12):2090-2097. PubMed ID: 27679524
[TBL] [Abstract][Full Text] [Related]
6. Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes.
Kim JH; Lee BH; Hyang Cho J; Kang E; Choi JH; Kim GH; Yoo HW
J Hum Genet; 2016 Nov; 61(11):923-929. PubMed ID: 27334365
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications.
Weidemann F; Niemann M; Störk S; Breunig F; Beer M; Sommer C; Herrmann S; Ertl G; Wanner C
J Intern Med; 2013 Oct; 274(4):331-41. PubMed ID: 23586858
[TBL] [Abstract][Full Text] [Related]
8. Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study.
Feriozzi S; Linhart A; Ramaswami U; Kalampoki V; Gurevich A; Hughes D;
Clin Ther; 2020 Dec; 42(12):2321-2330.e0. PubMed ID: 33218740
[TBL] [Abstract][Full Text] [Related]
9. The beneficial effects of long-term enzyme replacement therapy on cardiac involvement in Japanese Fabry patients.
Hongo K; Ito K; Date T; Anan I; Inoue Y; Morimoto S; Ogawa K; Kawai M; Kobayashi H; Kobayashi M; Ida H; Ohashi T; Taniguchi I; Yoshimura M; Eto Y
Mol Genet Metab; 2018 Jun; 124(2):143-151. PubMed ID: 29747997
[TBL] [Abstract][Full Text] [Related]
10. Enzyme replacement therapy improves cardiac features and severity of Fabry disease.
Motwani M; Banypersad S; Woolfson P; Waldek S
Mol Genet Metab; 2012 Sep; 107(1-2):197-202. PubMed ID: 22704481
[TBL] [Abstract][Full Text] [Related]
11. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.
Mignani R; Feriozzi S; Pisani A; Cioni A; Comotti C; Cossu M; Foschi A; Giudicissi A; Gotti E; Lozupone VA; Marchini F; Martinelli F; Bianco F; Panichi V; Procaccini DA; Ragazzoni E; Serra A; Soliani F; Spinelli L; Torti G; Veroux M; Cianciaruso B; Cagnoli L
Nephrol Dial Transplant; 2008 May; 23(5):1628-35. PubMed ID: 18057066
[TBL] [Abstract][Full Text] [Related]
12. Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience.
Thofehrn S; Netto C; Cecchin C; Burin M; Matte U; Brustolin S; Nunes AC; Coelho J; Tsao M; Jardim L; Giugliani R; Barros EJ
Ren Fail; 2009; 31(9):773-8. PubMed ID: 19925283
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.
Hopkin RJ; Cabrera G; Charrow J; Lemay R; Martins AM; Mauer M; Ortiz A; Patel MR; Sims K; Waldek S; Warnock DG; Wilcox WR
Mol Genet Metab; 2016 Sep; 119(1-2):151-9. PubMed ID: 27510433
[TBL] [Abstract][Full Text] [Related]
14. Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis.
Beck M; Hughes D; Kampmann C; Larroque S; Mehta A; Pintos-Morell G; Ramaswami U; West M; Wijatyk A; Giugliani R;
Mol Genet Metab Rep; 2015 Jun; 3():21-7. PubMed ID: 26937390
[TBL] [Abstract][Full Text] [Related]
15. Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis.
Kampmann C; Linhart A; Devereux RB; Schiffmann R
Clin Ther; 2009 Sep; 31(9):1966-76. PubMed ID: 19843486
[TBL] [Abstract][Full Text] [Related]
16. Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis.
Ramaswami U; Beck M; Hughes D; Kampmann C; Botha J; Pintos-Morell G; West ML; Niu DM; Nicholls K; Giugliani R;
Drug Des Devel Ther; 2019; 13():3705-3715. PubMed ID: 31749608
[TBL] [Abstract][Full Text] [Related]
17. Myocardial Storage, Inflammation, and Cardiac Phenotype in Fabry Disease After One Year of Enzyme Replacement Therapy.
Nordin S; Kozor R; Vijapurapu R; Augusto JB; Knott KD; Captur G; Treibel TA; Ramaswami U; Tchan M; Geberhiwot T; Steeds RP; Hughes DA; Moon JC
Circ Cardiovasc Imaging; 2019 Dec; 12(12):e009430. PubMed ID: 31826677
[TBL] [Abstract][Full Text] [Related]
18. Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.
Schaefer RM; Tylki-Szymańska A; Hilz MJ
Drugs; 2009 Nov; 69(16):2179-205. PubMed ID: 19852524
[TBL] [Abstract][Full Text] [Related]
19. Long-term changes in arterial structure and function and left ventricular geometry after enzyme replacement therapy in patients affected with Fabry disease.
Collin C; Briet M; Tran TC; Beaussier H; Benistan K; Bensalah M; Mousseaux E; Froissart M; Bozec E; Laurent S; Boutouyrie P; Germain DP
Eur J Prev Cardiol; 2012 Feb; 19(1):43-54. PubMed ID: 21450622
[TBL] [Abstract][Full Text] [Related]
20. Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study.
Madsen CV; Bundgaard H; Rasmussen ÅK; Sørensen SS; Petersen JH; Køber L; Feldt-Rasmussen U; Petri H
Scand Cardiovasc J; 2017 Aug; 51(4):207-216. PubMed ID: 28545342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]